 |
|
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98. Published online 2022 Oct 13 DOI: https://doi.org/10.3350/cmh.2022.0237
|
|
Citations to this article as recorded by
 Hypertension and NAFLD risk: Insights from the NHANES 2017–2018 and Mendelian randomization analyses
Mengqin Yuan, Jian He, Xue Hu, Lichao Yao, Ping Chen, Zheng Wang, Pingji Liu, Zhiyu Xiong, Yingan Jiang, Lanjuan Li
Chinese Medical Journal.2024; 137(4): 457. CrossRef MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1
Shuo Huang, Xia Xiao, Hongman Wu, Feng Zhou, Chenchao Fu
Irish Journal of Medical Science (1971 -).2024; 193(2): 909. CrossRef From NAFLD to MASLD: When metabolic comorbidity matters
Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Annals of Hepatology.2024; 29(2): 101281. CrossRef Machine learning-based integration identifies the ferroptosis hub genes in nonalcoholic steatohepatitis
Longfei Dai, Wenkang Yuan, Renao Jiang, Zhicheng Zhan, Liangliang Zhang, Xinjian Xu, Yuyang Qian, Wenqi Yang, Zhen Zhang
Lipids in Health and Disease.2024;[Epub] CrossRef Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub] CrossRef Effect of Blueberry Supplementation on a Diet-Induced Rat Model of Prediabetes—Focus on Hepatic Lipid Deposition, Endoplasmic Stress Response and Autophagy
Gonçalo Ferreira, Pedro Vieira, André Alves, Sara Nunes, Inês Preguiça, Tânia Martins-Marques, Tânia Ribeiro, Henrique Girão, Artur Figueirinha, Lígia Salgueiro, Manuela Pintado, Pedro Gomes, Sofia Viana, Flávio Reis
Nutrients.2024; 16(4): 513. CrossRef STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease
Zheng Mao, Jindong Zhao, Fan Cui, Zhen Li, Jinjin Cao, Jingjing Zhou, Mingliang Hou, Zengkun Qian
Tissue and Cell.2024; 88: 102345. CrossRef The Renin–Angiotensin System and Cardiovascular–Kidney–Metabolic Syndrome: Focus on Early-Life Programming
You-Lin Tain, Chien-Ning Hsu
International Journal of Molecular Sciences.2024; 25(6): 3298. CrossRef Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults
Jing Yan, Jun Zhou, Yuanyuan Ding, Chuantao Tu
Frontiers in Nutrition.2024;[Epub] CrossRef Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho
International Journal of Molecular Sciences.2024; 25(7): 3694. CrossRef Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clinical and Molecular Hepatology.2024; 30(2): 299. CrossRef Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways
Liping You, Tao Wang, Wenxuan Li, Jinghao Zhang, Chao Zheng, Yanxi Zheng, Suyin Li, Zhi Shang, Jiacheng Lin, Fang Wang, Yihan Qian, Zhijia Zhou, Xiaoni Kong, Yueqiu Gao, Xuehua Sun
Journal of Ethnopharmacology.2024; 329: 118165. CrossRef Adherence to an antioxidant diet and lifestyle is associated with reduced risk of cardiovascular disease and mortality among adults with nonalcoholic fatty liver disease: evidence from NHANES 1999–2018
Yingzi Li, Yipin Liu
Frontiers in Nutrition.2024;[Epub] CrossRef Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism.2024; 155: 155912. CrossRef Would Combination Be Better: Swimming Exercise and Intermittent Fasting Improve High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Obese Rats via the miR-122-5p/SREBP-1c/CPT1A Pathway
Kang Yang, Chengye Liu, Jun Shao, Lingxiang Guo, Qing Wang, Zhaoxiang Meng, Xing Jin, Xianghe Chen
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1675. CrossRef Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Yamei Li, Ping Qi, Si-Yuan Song, Yiping Wang, Hailian Wang, Peng Cao, Yu’e Liu, Yi Wang
Biomedicine & Pharmacotherapy.2024; 174: 116585. CrossRef Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage.2024;[Epub] CrossRef Neuregulin 4 as a novel adipokine in energy metabolism
Yuanbin Liu, Mingkai Chen
Frontiers in Physiology.2023;[Epub] CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
Frontiers in Endocrinology.2023;[Epub] CrossRef A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation
Junya Suzuki, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Biomedicines.2023; 11(5): 1295. CrossRef In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Young-Sun Lee, Ekihiro Seki
Cellular and Molecular Gastroenterology and Hepatology.2023; 16(3): 355. CrossRef Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef Obeticholic acid treatment of mice to promote fertilization and reproduction
Ming Liang, Huailiang Yang, Lanyong Xu, Longqiao Cao
Zygote.2023; 31(6): 527. CrossRef Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
Yuanbin Liu, Mingkai Chen
Frontiers in Nutrition.2023;[Epub] CrossRef Naringin ameliorates liver fibrosis in zebrafish by modulating IDO1-mediated lipid metabolism and inflammatory infiltration
Meng-chen Qin, Jun-jie Li, Yan-tao Zheng, Yun-jia Li, Yu-xue Zhang, Rou-xuan Ou, Wei-yi He, Jia-min Zhao, Su-tong Liu, Ming-hao Liu, Hai-yan Lin, Lei Gao
Food & Function.2023; 14(23): 10347. CrossRef Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample mendelian randomization study
Xuetong Ni, Chao Tong, Aheyeerke Halengbieke, Tengrui Cao, Jianmin Tang, Lixin Tao, Deqiang Zheng, Yumei Han, Qiang Li, Xinghua Yang
Diabetes Research and Clinical Practice.2023; 206: 110993. CrossRef Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Kamlesh K. Bhopale, Mukund P. Srinivasan
Livers.2023; 3(4): 597. CrossRef Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, Ziwei Huang, Xiong Xiao, Qing Zheng, Shengfu Li, Dan Long, Li Feng
International Journal of Molecular Sciences.2023; 24(24): 17514. CrossRef Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy
Guiyuan Jin, Xiaoying Yao, Dong Liu, Juan Zhang, Xiaobei Zhang, Yonghong Yang, Yanzhen Bi, Hui Zhang, Guanjun Dong, Huixin Tang, Shumin Cheng, Feng Hong, Meng Si
Immunity, Inflammation and Disease.2023;[Epub] CrossRef
|